安图生物
(603658)
| 流通市值:219.08亿 | | | 总市值:219.08亿 |
| 流通股本:5.71亿 | | | 总股本:5.71亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 3,239,525,111.2 | 2,057,927,123.1 | 992,202,191.51 | 4,226,413,277.24 |
| 营业总成本 | 2,367,660,745.1 | 1,551,661,922.35 | 758,254,185.72 | 3,171,017,904.49 |
| 其他经营收益 | | | | |
| 营业利润 | 940,134,711.63 | 549,675,743.28 | 262,754,207.9 | 1,217,929,013.35 |
| 利润总额 | 933,260,866.44 | 546,153,384.66 | 261,986,759.65 | 1,222,766,392.56 |
| 净利润 | 851,538,641.83 | 502,204,100.87 | 239,137,278.56 | 1,086,384,222.05 |
| 每股收益 | | | | |
| 其他综合收益 | -916,506.69 | -331,982.96 | -160,461.9 | -195,065.28 |
| 综合收益总额 | 850,622,135.14 | 501,872,117.91 | 238,976,816.66 | 1,086,189,156.77 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 5,929,614,076.34 | 5,512,857,627.56 | 6,093,324,729.44 | 6,308,275,297.16 |
| 非流动资产: | | | | |
| 非流动资产合计 | 6,407,305,304.44 | 6,271,244,752.27 | 6,148,893,448.97 | 5,981,449,834.54 |
| 资产总计 | 12,336,919,380.78 | 11,784,102,379.83 | 12,242,218,178.41 | 12,289,725,131.7 |
| 流动负债: | | | | |
| 流动负债合计 | 2,421,186,078.73 | 2,273,381,624.36 | 2,278,136,483.34 | 2,629,301,146.1 |
| 非流动负债: | | | | |
| 非流动负债合计 | 791,497,860.37 | 743,177,608.05 | 708,863,302.82 | 644,182,410.01 |
| 负债合计 | 3,212,683,939.1 | 3,016,559,232.41 | 2,986,999,786.16 | 3,273,483,556.11 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 9,023,762,254.54 | 8,674,379,764.28 | 9,162,441,066.51 | 8,926,154,166.03 |
| 股东权益合计 | 9,124,235,441.68 | 8,767,543,147.42 | 9,255,218,392.25 | 9,016,241,575.59 |
| 负债和股东权益合计 | 12,336,919,380.78 | 11,784,102,379.83 | 12,242,218,178.41 | 12,289,725,131.7 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 3,702,357,482.77 | 2,422,587,625.22 | 1,230,595,128.87 | 4,919,236,784.49 |
| 经营活动现金流出小计 | 3,168,660,914.36 | 2,206,745,664.19 | 1,084,022,628.37 | 3,577,555,021.74 |
| 经营活动产生的现金流量净额 | 533,696,568.41 | 215,841,961.03 | 146,572,500.5 | 1,341,681,762.75 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 7,788,222,713.01 | 6,035,997,435.48 | 2,227,823,742.53 | 4,980,273,193.85 |
| 投资活动现金流出小计 | 7,568,836,906.78 | 4,776,546,707.51 | 2,058,586,141.46 | 5,395,623,707.12 |
| 投资活动产生的现金流量净额 | 219,385,806.23 | 1,259,450,727.97 | 169,237,601.07 | -415,350,513.27 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,088,042,046.61 | 848,052,046.61 | 163,850,000 | 2,018,634,905.01 |
| 筹资活动现金流出小计 | 1,808,790,727.03 | 1,647,258,204.43 | 265,857,476.05 | 2,814,927,795.44 |
| 筹资活动产生的现金流量净额 | -720,748,680.42 | -799,206,157.82 | -102,007,476.05 | -796,292,890.43 |
| 汇率变动对现金及现金等价物的影响 | -25,274,361.4 | -17,706,566.05 | -7,662,969.99 | 774,015.75 |
| 现金及现金等价物净增加额 | 7,059,332.82 | 658,379,965.13 | 206,139,655.53 | 130,812,374.8 |
| 期末现金及现金等价物余额 | 589,930,056.43 | 1,241,250,688.74 | 789,010,379.14 | 582,870,723.61 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 658,379,965.13 | - | 130,812,374.8 |
最新报告期:2026-11-17| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 太平洋 | 谭紫媚 | 1.93 | 2.24 | 2.53 | 2026-11-17 |
| 华创证券 | 郑辰,张良龙,李婵娟 | 1.90 | 2.17 | 2.44 | 2026-11-13 |
| 中泰证券 | 祝嘉琦,谢木青 | 1.99 | 2.30 | 2.65 | 2026-10-30 |
| 兴业证券 | 东楠,孙媛媛,黄翰漾,龚涵清 | 1.97 | 2.19 | 2.54 | 2026-10-30 |
| 光大证券 | 黎一江 | 2.03 | 2.40 | 2.84 | 2026-10-29 |